Clinical Trial

miRNA in Chronic Kidney Diseases

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys promotes renal vascular remodeling and increases preglomerular resistance. These are key elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy. Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs (miRNAs) are regulators of gene expression and play a role in the progression of renal ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage under conditions of oxidative and ER stress remains understudied.
Trial Details
NCT Number NCT06316284
Lead Sponsor Josip Juraj Strossmayer University of Osijek
Collaborators: University Hospital Center Osijek
Conditions Chronic Kidney Diseases
Enrollment 90 participants
Start Date 2024-04-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-18